N
Google TrendJONAS BROTHERS (500+) — Jonas Brothers postpone Birmingham concert over weather concerns
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:jonas brothers500+steven kwan500+kings vs warriors200+steffi graf200+boxing200+ben simmons500+lisa500+bill maher500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Pharmacokinetics of CAR T" (30 stories)

Top Headline Story

Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly
Lead StoryNaturegeneral
Mar 31

Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3dXhHeFB5OVl1TndBX3kydWM1VDhUOUQzNjc2NlV3bUhxWURqakYxelhmYS1nZGdpWldOZDFwNVhXRnhRaFhvUmIwT1FPaUVvZldlOWtsOWpDUThqX2Zv?oc=5" target="_blank">Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+15m ago

jonas brothers

Jonas Brothers postpone Birmingham concert over weather concerns

Filter stories
500+15m ago

steven kwan

Guardians' Steven Kwan Could Shake Up Winter Outfield Market

Filter stories
200+15m ago

kings vs warriors

3 Storylines I'm Focused On in Warriors Preseason Game vs. Kings

Filter stories
200+15m ago

steffi graf

PICTURES: Steffi Graf & Daughter Jaz Feature In Andre Agassi’s ‘Photo Dump’ As Carlos Alcaraz & Karl-Anthony Towns Make Surprise Appearance

Filter stories

Search Results for "Pharmacokinetics of CAR T"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Optimal Fludarabine Exposure Linked to Improved Outcomes in CAR T-Cell Therapy for Large B-Cell Lymphoma
Medscapegeneral

Optimal Fludarabine Exposure Linked to Improved Outcomes in CAR T-Cell Therapy for Large B-Cell Lymphoma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPNmtKNWM1eV9vT1gxd0dBSUJmcXloY1h5Mkxpa3c4RFFRSzNPMU03WDJlWVpMb3Mzamh6XzJBSHlDbndRcFNoY212MVozT2hQNFNQYncxckF2Yk5KTjlVVjNMb3FHdXBlSDY4Q2x6MlhlM1pkb2JHWXlGOEc2ZEpYSGMwWlZydXdzNXVLTWIxRFh2cUR1ZzNUZm5VSjlxUzNNX2NVa3lOLVhIbElIaUE?oc=5" target="_blank">Optimal Fludarabine Exposure Linked to Improved Outcomes in CAR T-Cell Therapy for Large B-Cell Lymphoma</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
AJMCtech

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQSm5XWGstXzhVbVNMSGRDVDR4U2haM2pRN0RRT1Y3N1k2SzN3YTBhLU52ZmZnUnBoU0RWTmZxYTFFMWVVbmZSWE40ZG9reXRKeGdUYWstS3ZDUFFRQ2o1OGx1ZUV0QjlSZHcwS19zWHpCNmpzVDhIYUttZXBQek01MWE2TE1welF1U01HMGktdHpGbWJKMDJuR0xSUDVFZmRmcjhXdA?oc=5" target="_blank">Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas
OncLivegeneral

In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPQkxCc3F4NkRPc2NIZmlremdZYlhYam1aUjdfUTk1Vm40QllMa0t2WlhZWUh2MURYd3JNNDU2NTUzYmNmNDhaRTVMVFJWbl9RNmZtQmc1N2Q1Z1owc3ZvVHRJZTVvdmZEUHV2WUNScF9rWFVQSkd5MWFVVnZRYUIxM1lJSmgzR1FSTndXQm04VDBhQXFma2JwaW0xUThvOVhPQndib0JBeFV5NVNJc29fTHNHci1iS1h1T0xlQ3ZlME1PVGF2Sjh6Z1F2RFF3bkptNUs5dWNIbmc?oc=5" target="_blank">In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL
The ASCO Postgeneral

Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNSEV2SDlsb3I3UlhFYVAxZHp3Z3dYRG05WlBmR3FFd3MxTTJpMkNtSzdzekcwc28zdlAtMTljX3RaWGhuSm5FYk9aanNFSjFZMzRqd0Z3UGpxWDVlbW8tZC1IcnlQT0lvSG8zcnVjUFE2cFBFZnF6VmNrd1Vxb3FkRWJReVJKZ2p4QWNQWENldkc0WGpPb2N4aHJkSHpQdHU4TGQxWS1UU1RzM1ZINVBFV3BPdUNBS1o0UXRLMjVLSWE4czJ0TGYw?oc=5" target="_blank">Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
How to recover sufficient DNA from lymphodepleted CAR-T samples for VCN testing
News-Medicalgeneral

How to recover sufficient DNA from lymphodepleted CAR-T samples for VCN testing

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNcVZSaWhuQWp5U3d4WFZ4Q243UW9XTWFnaGVldWtBZUlhUkxYSWNEbUg1QUVjcDBScjBVaVFhVDBKdkFlVl9ySl83VDJFb1RNOU95b2RobDJXZmd2UGpycHdaNjZMVXNuQm1SUkt5RlJjblp5SUhMdl95RGhOMUMxYXZhRUV5bDVIRUxKbk5RQmYwb19ObVFqNnhnNFppZGVHS21jcDBIMEFnYlkxcFdIbFVWZXN4R1hfb2RoVg?oc=5" target="_blank">How to recover sufficient DNA from lymphodepleted CAR-T samples for VCN testing</a>  <font color="#6f6f6f">News-Medical</font>

Read Full StoryMore like this
Clinical pharmacology insights from recent cell and gene therapy approvals relevant to pediatrics
Naturegeneral

Clinical pharmacology insights from recent cell and gene therapy approvals relevant to pediatrics

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1VZ28xc1ZobWJ6MDlDWTZRay1qSUU1SVowY0tGVlF5TzRVRG1tem44dDZoc3BlMFJuOTZsNTRWYjVFTTVEdnpOei1QcUt4eVFJZWVGVFRMUmhncG83c0dr?oc=5" target="_blank">Clinical pharmacology insights from recent cell and gene therapy approvals relevant to pediatrics</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Critical considerations in the administration of antineoplastic therapy for patients with malignant solid tumors undergoing hemodialysis
Frontiersworld

Critical considerations in the administration of antineoplastic therapy for patients with malignant solid tumors undergoing hemodialysis

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOeEpjOHh4NVYycmNtajJlMmQyM1RBSHdSZG5PZV9oamZIMC11WExKeElSMkR2d0lVWkdxYVpWc1E3WmNaNGpHU2ZMMXlIMzJLdDI2SElFSUh1Z1Nib0F4OUVMRzZ6TTVSSXFnNFNfLTI5R1NLbHBHNFZKQ1piVGZIQ0FaUXZXM2pDUkJraDVB?oc=5" target="_blank">Critical considerations in the administration of antineoplastic therapy for patients with malignant solid tumors undergoing hemodialysis</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Wiley & Sonsgeneral

Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE5hcklDRzllaEtwVkNiOWVuaEVPTWhBb0lzZnZWS3R1aFpkazFOYzVGSGZvM2ExT0s0N2x2cnMtYlNFMTdIZGhhWE9zdmxNamJNclV0Zi1ZTUFnVC10WmZLUlQ0UkkxMVZScUYwV0lCVmEyUWM?oc=5" target="_blank">Pharmacokinetics of Odronextamab, A Bispecific T-Cell-Engaging Antibody, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma</a>  <font color="#6f6f6f">Wiley & Sons</font>

Read Full StoryMore like this
[ESMO 2025] CellabMED made phase 1 oral presentation on CAR-T targeting IL13Rα2
Korea Biomedical Reviewgeneral

[ESMO 2025] CellabMED made phase 1 oral presentation on CAR-T targeting IL13Rα2

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBsaVN2WjJFSmtkeDB2YWRiOE9yOFBMWktPWmpQczFpNkFYdzJjRlNMdlRzUHBscDkxVDU2UjdUNVlPXzAzZzlDWnctbzIzOWFlOGgtWEd2QV9aSGZGZmRxQ3duaEV0WmFYWGtDUC1B0gFyQVVfeXFMTmtnYXM1Nk1Sb0VLVTRjRVVDVzlsMlZfNnRieFFLbUtnU2pOWW1mWEpxRFBJZjRRZEJmQWpWMkdNQ2pwRkp4NzFqektaYmkxVmE1M1phU3FPRjNFbWdlVlZydkxBdDJaU0ZfaU9JSnBBWW93?oc=5" target="_blank">[ESMO 2025] CellabMED made phase 1 oral presentation on CAR-T targeting IL13Rα2</a>  <font color="#6f6f6f">Korea Biomedical Review</font>

Read Full StoryMore like this
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6
Science | AAASgeneral

Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9KdmxVcFQ2bEliT2JqaHJjUmEwRFpQNTBqZjBRU2Z0LXpxZFZ0b1hpYUV1eFZFdzdsd1RRZDdnWnZwTTlScC05Q25haU5OMUlXNHpwYXVhdTNJRnNjUHhJS0RQSXB5Snc?oc=5" target="_blank">Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6</a>  <font color="#6f6f6f">Science | AAAS</font>

Read Full StoryMore like this
CD19 CAR T-cell (BY19) therapy for Pediatric and Adult Patients with Relapsed or Refractory B-Cell Neoplasms in Belarus: Phase 1 trial
medRxivgeneral

CD19 CAR T-cell (BY19) therapy for Pediatric and Adult Patients with Relapsed or Refractory B-Cell Neoplasms in Belarus: Phase 1 trial

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE1SUTJZZHpfVzZoOURfa05Pd05SSzU2RUloVFpyS0pReC1UNlFGQ0tBY2E1dmVtampNVHFvaWxCcWRvZk0tc2E4VTVLUlg4X1N0bDJxSGU2MVljRmdMTlN5ZVFlT3BKN0tPZDhWQ0tJSE5EWmhOQlFZWW1mWQ?oc=5" target="_blank">CD19 CAR T-cell (BY19) therapy for Pediatric and Adult Patients with Relapsed or Refractory B-Cell Neoplasms in Belarus: Phase 1 trial</a>  <font color="#6f6f6f">medRxiv</font>

Read Full StoryMore like this
Phase I trial of LB2501: Novel in vivo CD19/CD20 CAR T-cell therapy for R/R B-NHL
Lymphoma Hubgeneral

Phase I trial of LB2501: Novel in vivo CD19/CD20 CAR T-cell therapy for R/R B-NHL

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOdjNLdXgzVlRiRjZsUDZ2OG9GeHM2WDdSNnZXcjhxcHFMZDRtdXdxNnZpOGIxc2JReWljSDlDNzBqeERPbHJyeGU0cV9KTU5nNGpSMHQzdy1CeHY2d1ZaV2NhdmVRaDlhaUJWbk53d19XLS12dEJ3V25rTzJHck1vRndIb3lfZlZCWklSQnlOTE9OeTZ0UTVlMkpNb2lXd0MwbDVXTFFPYkRjQ1ZJMC04YXNxNGxvSzgyTmp4UkhHOA?oc=5" target="_blank">Phase I trial of LB2501: Novel in vivo CD19/CD20 CAR T-cell therapy for R/R B-NHL</a>  <font color="#6f6f6f">Lymphoma Hub</font>

Read Full StoryMore like this
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics
Naturegeneral

Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9VaFZPREdvdElqal9rX2lsTXhhb1BCMFJjeWdIektpM2FremhvZFQ3N3pYcW1vSGNLdUswZVZJam1ad1N6NmROcWplbTZITlNBWHR1U0JzekdXOXZkU0g4?oc=5" target="_blank">Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy
Frontiersworld

Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPbmx3MzVGendqVWhVTmtycE1CdUJCWDBYcDdlcldvSE12Z2t5MU5COXp0XzNtQTBMd0JHdjFPT3ZhUzR4ZTVPWTRYaHhueWQ4NXdJa2JnQmpDbEF6WVhUdWtGZlBkMHBmYlYtVlFhQkN5NVRUUVh3YVdHeTh0eW1ZU1pQQU1aNVdRZVQ2NmJn?oc=5" target="_blank">Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
OncLivegeneral

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOLS1QMU9TdG02eXo2RXktdkxyUUJBOXUzX2tEdGllbFZLUVMwNDFoQmxNWG9iN2ZnSVZQMzRWTEM1eHpBNmtnOUpUNjNhUTUwNGhPcHpjRHZnVjBhemhpWFdfbEZYS2c5Um00czNIYmhPTERzZU40Y01XQkgxdHNMT3pORnEzOVRkVXhUSldqZmUwYVBYZVR3cUFRenhhZ0lNTGpQVGZnVWJ4ZzdvdEhyaFNjTmJqMWtB?oc=5" target="_blank">META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Anti-CD19 CAR T-cell therapy for autoimmune diseases: from exploratory clinical trials to quantitative pharmacodynamic modeling development
Frontiersworld

Anti-CD19 CAR T-cell therapy for autoimmune diseases: from exploratory clinical trials to quantitative pharmacodynamic modeling development

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPdC1RVVdBeVRhRGdZMXVRbjFaOG1zdi1rM3F2VEpKUEFteWFLREozQUpqWExic0htTzQ5ejl2UU5pN1RlMGxGWGU2ajdrMGlUM05tb0ZLN1dCdmFRZzdiS1BfNlN4eFp2dl9qNXZnQlhza1pjbHVaLWNGM2VyY3VsbDRFY3VjNEplRVFaUlJibHRsQQ?oc=5" target="_blank">Anti-CD19 CAR T-cell therapy for autoimmune diseases: from exploratory clinical trials to quantitative pharmacodynamic modeling development</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Deconvolution of clinical variance in CAR-T cell pharmacology and response
Naturegeneral

Deconvolution of clinical variance in CAR-T cell pharmacology and response

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1CNldoTkZGRXdLNmdKekY4bW44SEtfa3NRNXI4Y29RWTdYaDFfZHlQNUEtZldnNXVXN0kxenFMS0M5ZGpjbk9QQkJleWhuNXpWckliVlVFTjlHM2VhVTBF?oc=5" target="_blank">Deconvolution of clinical variance in CAR-T cell pharmacology and response</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously | Cancer Gene Therapy
Naturegeneral

An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously | Cancer Gene Therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBmMm1RbXJldzVFZUZiNzNVTFZoM2ViSmJPQmpoRXJhYU1SYW1LMXVxZkJmbTN2Z0V4TEpieF9zQ3RvTXZTdmtJM3p0UlZzclJiajRsaFU3Vk1NRFNlQ3Vj?oc=5" target="_blank">An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously | Cancer Gene Therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
Natureworld

Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ReG1rMnNWWHlxaDFvRnFxZFFvQzRvbzJDTk8xOWUtRGNrS3ZobEdzR29MejZOdFFjQVRaMWtHYlYzUndQQzlUdkcyc0FuRjlLYUlKd3lKLVo2QmhGTmdN?oc=5" target="_blank">Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Cartesian Therapeutics’ Myasthenia Gravis mRNA CAR-T Descartes-08 Garners FDA RMAT Designation
CGTLive®general

Cartesian Therapeutics’ Myasthenia Gravis mRNA CAR-T Descartes-08 Garners FDA RMAT Designation

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPem9rTGg0TnkwVTh2Z1FIYlN0Vkh0TzZTdzZxcEVRX0pDSkU4ZzBlNFExQkVqMWlEOEVobENNRHJZMnZkODJndkJSVHJYeFdzWjcyU2R3REo3ai1iMkJPR2V5NnJ4RzYzUjgxM3Bhd18xNVprTGtBNW80am1PRHVqekVMbEp6b2ZPSHFxVUE2VllabnNJX2ZoZlBBUFhpLXNKdktOUTNMQ3Fmc0VSdlE4MjVmVm1Kb0FzbnVISXlYbw?oc=5" target="_blank">Cartesian Therapeutics’ Myasthenia Gravis mRNA CAR-T Descartes-08 Garners FDA RMAT Designation</a>  <font color="#6f6f6f">CGTLive®</font>

Read Full StoryMore like this
CLDN6 CAR T-Cell Therapy Shows Encouraging Efficacy in Relapsed/Refractory Advanced Solid Tumors
OncLivegeneral

CLDN6 CAR T-Cell Therapy Shows Encouraging Efficacy in Relapsed/Refractory Advanced Solid Tumors

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOcXlyOFMxRF9FdkgyWGh6MkZUWnQzVnhlSlZ5R0JoUDJwX1FoR0ZQVEVYa09PUWFXLU52NWRyT0dBMU8weHBNOHZfdmlmMC1SbVV6UENmWThTLVU5T2ZlbjJDSnppNEpuSHRqYl81YlN4dHAxZ3NxNXVnVWF0ZU5hckN4ZzFSMEZiQXFHVk1VYXBkOURrZnVIV2N6SWJmS0Rrb2hHOFprQVU5Z0J2bDlZTGhZMUJFanU5WnVxS2xTMGJjTjQ?oc=5" target="_blank">CLDN6 CAR T-Cell Therapy Shows Encouraging Efficacy in Relapsed/Refractory Advanced Solid Tumors</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors
Science | AAASgeneral

Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0xQVU0QzM1NGg3ZlhWMzNoZFVlX2pFYjBOdkM0cVJ4Tm90bmFRMVlLd3p1NzZGY19tX2VTd2RkXy00aDdqYzVyaWtFS0lJUFUzZk5pZUI5OWtfMTBBVlNn?oc=5" target="_blank">Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors</a>  <font color="#6f6f6f">Science | AAAS</font>

Read Full StoryMore like this
Georg Schett, MD, on Exploring CAR-T for Autoimmune Disease
CGTLive®world

Georg Schett, MD, on Exploring CAR-T for Autoimmune Disease

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE02TFpEY1czMkhOSWdGT1o0T184M0VPaUpXNzdBeHZId3duVHhjcFFvY2RBVlFoRW9Ib0FwUlR2NmJpMmU4aHpUMG5yTW9pLXQxekZ2dXdadUVlY0NhdmdlcVoxMXphY2xIelMtNHV1ZTI2dFJIY3V6TUhR?oc=5" target="_blank">Georg Schett, MD, on Exploring CAR-T for Autoimmune Disease</a>  <font color="#6f6f6f">CGTLive®</font>

Read Full StoryMore like this
Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction
Wiley Online Librarytech

Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1Kd0lldVR6QW5nSzFFdnd6QkVPQ0dsanpKX0lpODJNMUpNSHVMR3pRSVNNak1KVGVZc2JsMnE1UTBLX3hqR2xFbnhUel9nWHkxNGNXTUxZOHRmeEhGbzhkcjFnTmZuODBXbHE4OUlR?oc=5" target="_blank">Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Practical considerations for clinical translation of PET imaging of adoptive cell therapies
Naturegeneral

Practical considerations for clinical translation of PET imaging of adoptive cell therapies

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0xdlpoV2dSd05fb3EyaTN4VzBhQUd0VENBRXl2Sm1nYkxnNlhzNWN4bnpNTmdyVi1iRXB1WW90Nl9QYldubUhfTlZYZWlvWHRRNXg2VC1mUTNNM05RQ3Rr?oc=5" target="_blank">Practical considerations for clinical translation of PET imaging of adoptive cell therapies</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Vispa-Cel Shows Comparable Efficacy, Durability to Autologous CAR T-Cell Therapy in R/R B-Cell NHL
OncLivegeneral

Vispa-Cel Shows Comparable Efficacy, Durability to Autologous CAR T-Cell Therapy in R/R B-Cell NHL

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPVllWWnJIM3g0QXk5VXNQb3Q0dmJ5SmhXWXlMemxTU2JOQVQwQWN2NHk0dF9zUkp3c0IxLTNkRFFfbGY4T0NJdXg5cl95TWg5VlY5U2ZDYWROVC1mcFRPakcwcGNRNjVyNk1qYW04OUhwVERWZzF1X0xXS0xRSlFNcnBTZVpLMGZpYnB2YjU4X3VmN1BKdXExX09fcE11VllFaTN5UExReFlCYjV5TDdlN19ndHB1QkU1LTcwc2syZnZhY1VV?oc=5" target="_blank">Vispa-Cel Shows Comparable Efficacy, Durability to Autologous CAR T-Cell Therapy in R/R B-Cell NHL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
BCMA/CD19–Targeting CAR T-Cell Therapy Is Effective in Newly Diagnosed Multiple Myeloma
OncLivegeneral

BCMA/CD19–Targeting CAR T-Cell Therapy Is Effective in Newly Diagnosed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQTWNGWk90YmJ4UXBNZnNxR0VZYk5WSzhWTHF6cVNfaF9Ja3hFbnhWTHQwTE0tYWtJZnZrazFTNTcwTUhfU3BQQXMzbHBrU3FjdTk3Uk8xa3kwOVk1dzBmNHMyRHI5SVEtTlcxOE8zOFNKS0Jqa2Zpb21yeGdFQnZ2YWhzRnMxS0wyVmlhT0hEeGU2NnVHUGZ3MGpxTFZlOUJIaTVqMTNETnVTcUR6WE1zQnZ2VVktcDA?oc=5" target="_blank">BCMA/CD19–Targeting CAR T-Cell Therapy Is Effective in Newly Diagnosed Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges
Naturegeneral

Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE85UTJWM3hRclJWY1JqOVhFNDd6VkppYTBtTkJnY2FPbHFQZnFSc1FmQ3VJbDNMREVXTGNvamh5Zmx2eW5CWGt4c1Y2Zkk0NVNUdmhHaU5nOFdraC00MUVZ?oc=5" target="_blank">Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
FDA Pauses iMMagine-1 Study of CART-ddBCMA in Relapsed/Refractory Multiple Myeloma
Targeted Oncologygeneral

FDA Pauses iMMagine-1 Study of CART-ddBCMA in Relapsed/Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQOG1PdnhZb29Pc0RoeHllTkt3VkQzc2NGbWtIV0s0YV95Mm5PRnFWR2hnaElYOHJMSmswYS1SeW96NUVxRU80bEhVMnhJNDBTb2RpLS1ycEN2eDNUNlFpUm1EVDR6MTluSktfV3ZubE5aYXZyQ0VvZDFKM2tSZVVVYkE2RXdKOUtKMVdNRFJUbWpKS1hCTWpMbnRwUnBKT2JoeHVQRU5SczNndlBSSXhOb0dLczlLQQ?oc=5" target="_blank">FDA Pauses iMMagine-1 Study of CART-ddBCMA in Relapsed/Refractory Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
"Pharmacokinetics of CAR T" — Live Google News Trends & Headlines